8-K: Y-mAbs Reports Q1 2025 Financial Results: Revenue Up, Focus on Radiopharmaceutical Pipeline

Y-mAbs Therapeutics reports an 8% increase in DANYELZA net product revenue for Q1 2025, alongside advancements in their radiopharmaceutical programs.

Summary

• Y-mAbs Therapeutics announced its Q1 2025 financial results, with total revenues of $20.9 million, a 5% increase compared to $19.9 million in Q1 2024.
• DANYELZA net product revenues increased by 8% to $20.9 million.
• U.S. DANYELZA revenue decreased by 28% to $13.4 million due to clinical study enrollments and market dynamics.
• Ex-U.S. DANYELZA revenue increased significantly to $7.5 million, driven by growth in Western Asia, Eastern Asia, and Latin America.
• The company's cash and cash equivalents stood at $60.3 million as of March 31, 2025.
• Y-mAbs reiterates its full-year 2025 revenue guidance of $75 million to $90 million.
• The company expects Q2 2025 total revenues to be between $17 million and $19 million.
• A net loss of $5.2 million, or ($0.12) per share, was reported for Q1 2025, compared to a net loss of $6.6 million, or ($0.15) per share, in Q1 2024.
• The company is organized into two business units: DANYELZA and Radiopharmaceuticals.
• The first patient was dosed in the CD38-SADA Phase 1 clinical trial (Trial 1201) for relapsed or refractory non-Hodgkin Lymphoma.
• Y-mAbs plans to host a virtual Radiopharmaceutical R&D update on May 28, 2025, to discuss clinical data and pipeline strategy.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The company shows revenue growth and advancements in its pipeline, but there are concerns about declining U.S. sales and increasing expenses. The reiteration of financial guidance and cash runway provide some reassurance.

Positives

• Total revenues increased by 5% compared to the same quarter last year.
• DANYELZA net product revenues saw an 8% increase.
• Ex-U.S. DANYELZA revenue experienced substantial growth.
• The company reiterates its full-year 2025 revenue guidance.
• The company has sufficient cash to fund operations into 2027.
• The first patient was dosed in the CD38-SADA Phase 1 clinical trial (Trial 1201).
• Naxitamab-gqgk (DANYELZA) has been recommended by the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) as a NCCN Category 2A treatment option for high-risk neuroblastoma.

Negatives

• U.S. DANYELZA revenue decreased by 28% due to clinical study enrollments and market dynamics.
• Gross margins decreased from 89% to 86% due to lower margins in Ex-U.S. regions.
• Selling, general, and administrative expenses increased by $1.7 million.

Risks

• The company's estimate that cash and cash equivalents will be sufficient to fund operations into 2027 is based on assumptions that may prove inaccurate.
• The company's business plan is supported by assumptions that may prove to be inaccurate, such that YmAbs could use its available capital resources sooner than it currently expects.
• The decline in U.S. DANYELZA net product revenues was driven by enrollments in clinical studies and market dynamics.

Future Outlook

Y-mAbs anticipates total revenues between $75 million and $90 million for the full year 2025 and between $17 million and $19 million for the second quarter of 2025. The company expects its cash and cash equivalents to be sufficient to fund operations into 2027.

Management Comments

• Michael Rossi, President and Chief Executive Officer, stated that the company demonstrated solid DANYELZA net product revenue, advancement of the SADA PRIT platform, and prudent operational spending in Q1 2025.
• Michael Rossi mentioned the company was pleased to have dosed the first patient in Trial 1201, highlighting the potential of pretargeted radioimmunotherapy.
• Michael Rossi noted the company began operating as two separate business units, DANYELZA and Radiopharmaceuticals, starting in Q1 2025.

Industry Context

Y-mAbs' focus on radioimmunotherapy and antibody-based therapeutics aligns with the growing interest in targeted cancer treatments. The NCCN's recommendation of DANYELZA underscores its importance in the neuroblastoma treatment landscape. The company's strategic shift to focus on radiopharmaceuticals reflects a broader industry trend towards personalized medicine and targeted therapies.

Comparison to Industry Standards

• Y-mAbs' gross margin of 86% is relatively high compared to some other biopharmaceutical companies, but is lower than the 89% reported in the same period last year.
• Companies like Seagen, which also focuses on antibody-drug conjugates, have reported varying gross margins depending on product mix and royalty structures.
• The company's cash runway into 2027 is a positive sign, but it's crucial to monitor cash burn and potential future capital needs.
• Other companies in the radiopharmaceutical space, such as Novartis with its Pluvicto, are also investing heavily in R&D and clinical trials.

Stakeholder Impact

• Shareholders can expect continued investment in the radiopharmaceutical platform and potential growth in DANYELZA sales.
• Patients may benefit from the advancement of new cancer therapies.
• Employees will be impacted by the business realignment and focus on two separate business units.

Next Steps

• The company will host a virtual Radiopharmaceutical R&D update on May 28, 2025.
• Y-mAbs will continue to advance its clinical trials, including the CD38-SADA Phase 1 trial.
• The company will focus on expanding the commercial reach of DANYELZA, particularly in Ex-U.S. markets.

Key Dates

Keywords

Y-mAbs, DANYELZA, Radiopharmaceutical, Neuroblastoma, Non-Hodgkin Lymphoma, Financial Results, Revenue, Clinical Trial, SADA PRIT, NCCN